Literature DB >> 20692454

Human de-epidermized dermis as a stem cell carrier.

E Pianigiani1, F Ierardi, B Mazzanti, R Saccardi, C Cuciti, M Fimiani.   

Abstract

Recently several types of skin equivalents have been developed, consisting of differentiated keratinocytes cultured on various dermal substitutes. Different models of reconstructed human skin have been proposed, such as human and animal de-epidermized dermis, inert filters, collagen matrices, lyophilized collagen membranes populated with fibroblasts, and other models populated with melanocytes and/or Langerhans cells. These skin equivalents mimic native skin in vivo. They have provided information about dermal-epidermal interactions, cell-cell, and cell-matrix interactions; responses of dermal and epithelial cells to biological signals and pharmacological agents; as well as effects of drugs and growth factors on wound healing. Human allodermis from tissue banks has been used for clinical purposes, namely, as support for autologous keratinocyte cultures and as a potentially ideal scaffold for dermal replacement. This bioproduct is considered to be the most suitable clinical carrier for autologous fibroblasts and keratinocytes, as well as an useful experimental model to study angiogenesis and to stimulate vascularization in reconstructed human skin. Because it is human-derived, it is in our opinion the safest of all available types of skin equivalent. Having epidermal and dermal structures, it can be used in one-stage grafting procedures for wound closure. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692454     DOI: 10.1016/j.transproceed.2010.05.040

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Authors:  Paola Indovina; Eleonora Marcelli; Domenico Di Marzo; Nadia Casini; Iris Maria Forte; Francesca Giorgi; Luigi Alfano; Francesca Pentimalli; Antonio Giordano
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

2.  SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.

Authors:  Nadia Casini; Iris Maria Forte; Gianmarco Mastrogiovanni; Francesca Pentimalli; Adriano Angelucci; Claudio Festuccia; Valentina Tomei; Elisa Ceccherini; Domenico Di Marzo; Silvia Schenone; Maurizio Botta; Antonio Giordano; Paola Indovina
Journal:  Oncotarget       Date:  2015-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.